Lee Frederick Schroeder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lee Frederick Schroeder has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- David A. Opare
Ghana Health Service
2 shared publications David F. Keren
Department of Pathology, University of Michigan School of Medicine, United States
2 shared publicationsDavid M. Manthei
Department of Pathology, University of Michigan School of Medicine, United States
2 shared publicationsDavid W. Dowdy
Affiliation Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publicationsErnest Kenu
Affiliation School of Public Health, University of Ghana, Accra, Ghana
2 shared publications- Ernest Kenu
Ghana Field Epidemiology and Laboratory Training Programme, School of Public Health, University of Ghana, Accra, Ghana
2 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by BMJ in Considerations in Medicine
- Vol. 4 (1) , e000021
Scaling global pathology education: insights from the Global Pathology and Laboratory Medicine Consortium (GPALMC) summit at University of Michigan
Objectives To identify structural and systemic barriers to pathology education in low- and middle-income countries (LMICs), evaluate emerging digital and AI-driven solutions and develop consensus-based frameworks for sustainable diagnostic capacity building. Design Expert consensus-based synthesis. Qualitative synthesis of inaugural Global Pathology and Laboratory Medicine Consortium (GPALMC) summit proceedings using facilitated deliberative consensus, transcript-based thematic analysis with artificial intelligence (AI)-assisted synthesis and human oversight, triangulated with a scoping literature review. Setting University of Michigan, Ann Arbor, USA. Participants 20 multidisciplinary experts from eight countries spanning sub-Saharan Africa, North Africa, the Middle East, Latin America and North America, including pathologists, surgeons, public health officials and medical educators. Main outcome measures Identification of critical gaps in pathology training; refinement of the Residency in a Box cloud-based model with four LMIC-specific prerequisites, development of five interdependent strategic axes and policy recommendations on workforce retention, digital infrastructure and governance. Results Nearly 47% of the global population lacks access to essential diagnostics. Primary barriers include brain drain, infrastructure deficits and curricula misaligned with local disease burdens. Digital pathology and AI offer transformative potential but are hindered by high costs of ownership and a lack of diverse training datasets. Models from Ghana, Rwanda, India, Ethiopia and Nigeria confirm sustainable progress requires government ownership, phased implementation and integrated governance. Conclusions Scaling global pathology education requires a shift from donor-dependent aid towards nationally owned health system strengthening. The GPALMC framework integrates cloud-based training, bidirectional mentorship, contextualised curricula and diversified financing to close the diagnostic gap and advance health equity.
- 18 May 2026
- Published by BMJ in Considerations in Medicine
- Vol. 4 (1) , e000021
Open AccessScaling global pathology education: insights from the Global Pathology and Laboratory Medicine Consortium (GPALMC) summit at University of Michigan
Objectives To identify structural and systemic barriers to pathology education in low- and middle-income countries (LMICs), evaluate emerging digital and AI-driven solutions and develop consensus-based frameworks for sustainable diagnostic capacity building. Design Expert consensus-based synthesis. Qualitative synthesis of inaugural Global Pathology and Laboratory Medicine Consortium (GPALMC) summit proceedings using facilitated deliberative consensus, transcript-based thematic analysis with artificial intelligence (AI)-assisted synthesis and human oversight, triangulated with a scoping literature review. Setting University of Michigan, Ann Arbor, USA. Participants 20 multidisciplinary experts from eight countries spanning sub-Saharan Africa, North Africa, the Middle East, Latin America and North America, including pathologists, surgeons, public health officials and medical educators. Main outcome measures Identification of critical gaps in pathology training; refinement of the Residency in a Box cloud-based model with four LMIC-specific prerequisites, development of five interdependent strategic axes and policy recommendations on workforce retention, digital infrastructure and governance. Results Nearly 47% of the global population lacks access to essential diagnostics. Primary barriers include brain drain, infrastructure deficits and curricula misaligned with local disease burdens. Digital pathology and AI offer transformative potential but are hindered by high costs of ownership and a lack of diverse training datasets. Models from Ghana, Rwanda, India, Ethiopia and Nigeria confirm sustainable progress requires government ownership, phased implementation and integrated governance. Conclusions Scaling global pathology education requires a shift from donor-dependent aid towards nationally owned health system strengthening. The GPALMC framework integrates cloud-based training, bidirectional mentorship, contextualised curricula and diversified financing to close the diagnostic gap and advance health equity.
- Open Access
- 1 January 2026
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 15 (1) , 8
Implementing laboratory quality management systems in Ghana: A quality audit of accreditation readiness in clinical and public health laboratories (2021–2023)
Background: The Stepwise Laboratory Improvement Process Towards Accreditation (SLIPTA) checklist has demonstrated improvement in laboratory quality in Africa. In Ghana, however, implementation has targeted mainly higher-tier clinical laboratories. A balanced approach across the laboratory network is needed to strengthen national laboratory quality. Objective: To evaluate the quality management performance and accreditation readiness of clinical and public health laboratories (PHLs) in Ghana. Methods: Using a modified SLIPTA checklist, we audited randomly selected clinical and PHLs from districts in the three ecological zones from February 2021 to November 2023. Analyses employed Wilcoxon rank-sum tests, Kruskal-Wallis tests, and quantile regression to assess associations between laboratory characteristics and SLIPTA scores. Results: Forty-five health facilities and four PHLs were audited: 80% of facilities were in the public sector. Laboratories performed a median of 24 (Interquartile range [IQR]: 10–70) tests daily. The median SLIPTA score was 50% (IQR: 35% – 58%), with hospitals recording the highest scores [median, IQR: 58% (51% – 61%)]. Of the 12 SLIPTA quality systems essentials, laboratories performed highest in organisation and personnel. In multivariable regression, facility location in the Northern zone (adjusted coefficient = –23, 95%CI = –38 to –8; p < 0.001) was negatively associated with SLIPTA scores compared to the Southern zone. Conclusion: More hospitals and PHLs had achieved a minimum one-star rating towards International Organization for Standardization accreditation readiness during the quality audit. Persistent gaps in client management, internal audits, and corrective actions require targeted training and mentoring to support effective implementation of improvement initiatives. What this study adds: This study provides the first nationwide quality audit of a representative sample of clinical laboratories and PHLs in Ghana with a balanced representation of health facilities in the tiered laboratory network, underscoring the need for a more inclusive, sustainable approach to laboratory quality improvement across the tiered network of the country.
- 1 January 2026
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 15 (1) , 8
Open AccessImplementing laboratory quality management systems in Ghana: A quality audit of accreditation readiness in clinical and public health laboratories (2021–2023)
Background: The Stepwise Laboratory Improvement Process Towards Accreditation (SLIPTA) checklist has demonstrated improvement in laboratory quality in Africa. In Ghana, however, implementation has targeted mainly higher-tier clinical laboratories. A balanced approach across the laboratory network is needed to strengthen national laboratory quality. Objective: To evaluate the quality management performance and accreditation readiness of clinical and public health laboratories (PHLs) in Ghana. Methods: Using a modified SLIPTA checklist, we audited randomly selected clinical and PHLs from districts in the three ecological zones from February 2021 to November 2023. Analyses employed Wilcoxon rank-sum tests, Kruskal-Wallis tests, and quantile regression to assess associations between laboratory characteristics and SLIPTA scores. Results: Forty-five health facilities and four PHLs were audited: 80% of facilities were in the public sector. Laboratories performed a median of 24 (Interquartile range [IQR]: 10–70) tests daily. The median SLIPTA score was 50% (IQR: 35% – 58%), with hospitals recording the highest scores [median, IQR: 58% (51% – 61%)]. Of the 12 SLIPTA quality systems essentials, laboratories performed highest in organisation and personnel. In multivariable regression, facility location in the Northern zone (adjusted coefficient = –23, 95%CI = –38 to –8; p < 0.001) was negatively associated with SLIPTA scores compared to the Southern zone. Conclusion: More hospitals and PHLs had achieved a minimum one-star rating towards International Organization for Standardization accreditation readiness during the quality audit. Persistent gaps in client management, internal audits, and corrective actions require targeted training and mentoring to support effective implementation of improvement initiatives. What this study adds: This study provides the first nationwide quality audit of a representative sample of clinical laboratories and PHLs in Ghana with a balanced representation of health facilities in the tiered laboratory network, underscoring the need for a more inclusive, sustainable approach to laboratory quality improvement across the tiered network of the country.
- Open Access
- 17 November 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (11) , e0005302
Evaluating the impact of decentralized testing for tuberculosis in Ghana: A simulation model
Poor geographical accessibility to tuberculosis (TB) diagnostic services in Ghana is a key barrier to timely diagnosis. Decentralizing molecular testing for TB could improve TB case notification among underserved populations and enhance treatment initiation while avoiding unnecessary treatments. This study aims to project the epidemiological impact of decentralized TB testing at the country level. We developed an individual-based simulation of the TB diagnostic system and treatment cascade in Ghana, calibrated to key TB care targets using data from the District Health Information Management System (DHIMSII) from 2019-2022. We assessed the effects of expanding molecular (Xpert MTB/RIF) testing to (1) all 218 district hospitals and (2) all 703 modeled facilities reporting TB notifications, comparing these scenarios to the current diagnostic network. Under the baseline scenario, 26% of samples remained untested, with over 30% of diagnoses made through clinical judgment alone, and 35% with false positive diagnoses. Decentralizing Xpert to district-level facilities could reduce the proportion of untested samples to 20%, lowering false positive diagnosis to 32%. While projected TB notifications and treatment rates in 2030 remained similar, this shift could result in 51 additional treatment initiations for individuals with undiagnosed TB, prevent 36 unnecessary treatments, and save 43 lives per million people over an eight-year period by 2030. Full Xpert decentralization could eliminate untested samples by enabling on site testing at all facilities, reduce false positive diagnosis to 25%, and lead to 220 additional treatment initiations, 140 fewer unnecessary treatments, and 180 lives saved per million relative to baseline from 2023-2030. Decentralizing Xpert testing offers significant benefits, improving diagnostic accuracy, reducing untested samples, and enhancing TB treatment outcomes – but wide-scale implementation is required to realize full benefits at a country level.
- 17 November 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (11) , e0005302
Open AccessEvaluating the impact of decentralized testing for tuberculosis in Ghana: A simulation model
Poor geographical accessibility to tuberculosis (TB) diagnostic services in Ghana is a key barrier to timely diagnosis. Decentralizing molecular testing for TB could improve TB case notification among underserved populations and enhance treatment initiation while avoiding unnecessary treatments. This study aims to project the epidemiological impact of decentralized TB testing at the country level. We developed an individual-based simulation of the TB diagnostic system and treatment cascade in Ghana, calibrated to key TB care targets using data from the District Health Information Management System (DHIMSII) from 2019-2022. We assessed the effects of expanding molecular (Xpert MTB/RIF) testing to (1) all 218 district hospitals and (2) all 703 modeled facilities reporting TB notifications, comparing these scenarios to the current diagnostic network. Under the baseline scenario, 26% of samples remained untested, with over 30% of diagnoses made through clinical judgment alone, and 35% with false positive diagnoses. Decentralizing Xpert to district-level facilities could reduce the proportion of untested samples to 20%, lowering false positive diagnosis to 32%. While projected TB notifications and treatment rates in 2030 remained similar, this shift could result in 51 additional treatment initiations for individuals with undiagnosed TB, prevent 36 unnecessary treatments, and save 43 lives per million people over an eight-year period by 2030. Full Xpert decentralization could eliminate untested samples by enabling on site testing at all facilities, reduce false positive diagnosis to 25%, and lead to 220 additional treatment initiations, 140 fewer unnecessary treatments, and 180 lives saved per million relative to baseline from 2023-2030. Decentralizing Xpert testing offers significant benefits, improving diagnostic accuracy, reducing untested samples, and enhancing TB treatment outcomes – but wide-scale implementation is required to realize full benefits at a country level.
- 6 March 2024
- Published by SAGE Publications in Medical Decision Making
- Vol. 44 (3) , 307-319
A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing
Background: Laboratory networks provide services through onsite testing or through specimen transport to higher-tier laboratories. This decision is based on the interplay of testing characteristics, treatment characteristics, and epidemiological characteristics. Objectives: Our objective was to develop a generalizable model using the threshold approach to medical decision making to inform test placement decisions. Methods: We developed a decision model to compare the incremental utility of onsite versus send-out testing for clinical purposes. We then performed Monte Carlo simulations to identify the settings under which each strategy would be preferred. Tuberculosis was modeled as an exemplar. Results: The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. When the sensitivity decrements of onsite testing were minimal, onsite testing tended to be preferred when send-out delays reduced clinical utility by >20%. By contrast, when onsite testing incurred large reductions in sensitivity, onsite testing tended to be preferred when utility lost due to delays was >50%. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs. Conclusions: Decision makers can select onsite versus send-out testing in an evidence-based fashion using estimates of the percentage of clinical utility lost due to send-out delays and the relative accuracy of onsite versus send-out testing. This model is designed to be generalizable to a wide variety of use cases. Highlights: The design of laboratory networks, including the decision to place diagnostic instruments at the point-of-care or at higher tiers as accessed through specimen transport, can be informed using the threshold approach to medical decision making. The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. The threshold approach to medical decision making can be used to compare point-of-care testing accuracy decrements with the lost utility of treatment due to send-out testing delays. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs.
- 6 March 2024
- Published by SAGE Publications in Medical Decision Making
- Vol. 44 (3) , 307-319
A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing
Background: Laboratory networks provide services through onsite testing or through specimen transport to higher-tier laboratories. This decision is based on the interplay of testing characteristics, treatment characteristics, and epidemiological characteristics. Objectives: Our objective was to develop a generalizable model using the threshold approach to medical decision making to inform test placement decisions. Methods: We developed a decision model to compare the incremental utility of onsite versus send-out testing for clinical purposes. We then performed Monte Carlo simulations to identify the settings under which each strategy would be preferred. Tuberculosis was modeled as an exemplar. Results: The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. When the sensitivity decrements of onsite testing were minimal, onsite testing tended to be preferred when send-out delays reduced clinical utility by >20%. By contrast, when onsite testing incurred large reductions in sensitivity, onsite testing tended to be preferred when utility lost due to delays was >50%. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs. Conclusions: Decision makers can select onsite versus send-out testing in an evidence-based fashion using estimates of the percentage of clinical utility lost due to send-out delays and the relative accuracy of onsite versus send-out testing. This model is designed to be generalizable to a wide variety of use cases. Highlights: The design of laboratory networks, including the decision to place diagnostic instruments at the point-of-care or at higher tiers as accessed through specimen transport, can be informed using the threshold approach to medical decision making. The most important determinants of the decision to test onsite versus send-out were the clinical utility lost due to send-out testing delays and the accuracy decrement with onsite testing. The threshold approach to medical decision making can be used to compare point-of-care testing accuracy decrements with the lost utility of treatment due to send-out testing delays. The relative cost of onsite versus send-out testing affected these thresholds, particularly when testing costs were >10% of treatment costs.
- Open Access
- 20 July 2023
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 12 (1) , 8
Providing specimen transport through an online marketplace in the Northern region of Ghana
The African Journal of Laboratory Medicine focuses on the role of the laboratory and its professionals in the clinical and public healthcare sectors, and is specifically based on an African frame of reference.
- 20 July 2023
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 12 (1) , 8
Open AccessProviding specimen transport through an online marketplace in the Northern region of Ghana
The African Journal of Laboratory Medicine focuses on the role of the laboratory and its professionals in the clinical and public healthcare sectors, and is specifically based on an African frame of reference.
- Open Access
- 1 October 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-11
Rational design of an essential diagnostics network to support Universal Health Coverage: a modeling analysis
Background: Diagnostic investigations, including pathology and laboratory medicine (PALM) and radiology, have been largely absent from international strategies such as the Sustainable Development Goals. Further, there is little international guidance on which health system tiers different diagnostics should be placed, a critical step in developing a country-level diagnostics network. We describe a modeling strategy to produce tier-specific diagnostic recommendations based on disease burden, current treatment pathways, and existing infrastructure in a country. Methods: The relational model assumes that diagnostics should be available at the lowest tier where patients might receive medical management. Using Ghana as an exemplar, the 20 diseases forecasted by 2030 and 2040 to cause the greatest burden in low- and middle-income countries were mapped to three generalized tiers in the Ghanaian health system (Primary, Secondary, and Tertiary care) for three levels of each disease (triage, uncomplicated, and complicated). The lowest tier at which a diagnostic could potentially be placed was restricted by existing infrastructure, though placement still required there be a medical justification for the diagnostic at that tier. Results: The model recommended 111 unique diagnostic investigations with 17 at Primary tier, an additional 45 at Secondary tier and a further 49 at Tertiary tier. Estimated capital costs were $8,330 at Primary tier and between $571,000 to $777,000 at Secondary tier. Twenty-eight different laboratory tests were recommended as send-outs from Primary to Secondary tier, and twelve as send-outs to Tertiary tier. Conclusions: This model provides a transparent framework within which countries can customize diagnostic planning to local disease priorities, health system patient treatment pathways, and infrastructural limitations to best support Universal Health Coverage.
- 1 October 2022
- Published by Springer Nature in BMC Health Services Research
- Vol. 22 (1) , 1-11
Open AccessRational design of an essential diagnostics network to support Universal Health Coverage: a modeling analysis
Background: Diagnostic investigations, including pathology and laboratory medicine (PALM) and radiology, have been largely absent from international strategies such as the Sustainable Development Goals. Further, there is little international guidance on which health system tiers different diagnostics should be placed, a critical step in developing a country-level diagnostics network. We describe a modeling strategy to produce tier-specific diagnostic recommendations based on disease burden, current treatment pathways, and existing infrastructure in a country. Methods: The relational model assumes that diagnostics should be available at the lowest tier where patients might receive medical management. Using Ghana as an exemplar, the 20 diseases forecasted by 2030 and 2040 to cause the greatest burden in low- and middle-income countries were mapped to three generalized tiers in the Ghanaian health system (Primary, Secondary, and Tertiary care) for three levels of each disease (triage, uncomplicated, and complicated). The lowest tier at which a diagnostic could potentially be placed was restricted by existing infrastructure, though placement still required there be a medical justification for the diagnostic at that tier. Results: The model recommended 111 unique diagnostic investigations with 17 at Primary tier, an additional 45 at Secondary tier and a further 49 at Tertiary tier. Estimated capital costs were $8,330 at Primary tier and between $571,000 to $777,000 at Secondary tier. Twenty-eight different laboratory tests were recommended as send-outs from Primary to Secondary tier, and twelve as send-outs to Tertiary tier. Conclusions: This model provides a transparent framework within which countries can customize diagnostic planning to local disease priorities, health system patient treatment pathways, and infrastructural limitations to best support Universal Health Coverage.
- Open Access
- 10 November 2021
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (3) , 661-673
Predicting Direct-Specimen SARS-CoV-2 Assay Performance Using Residual Patient Samples
Background: Diagnostic sensitivities of point-of-care SARS-CoV-2 assays depend on specimen type and population-specific viral loads. Evaluation of these assays require “direct” specimens from paired-swab studies rather than more accessible residual specimens in viral transport media (VTM). Methods: Residual VTM and limit-of-detection studies were conducted on Abbott ID NOW™ COVID-19, Quidel Sofia 2™ SARS Antigen FIA, and DiaSorin Simplexa™ COVID-19 Direct assays, with cycle threshold (CT) adjustments to approximate direct-specimen testing based on gene-target doubling each PCR cycle. Logistic regression was used to model assay performance by specimen CT. These models were applied to CT distributions of symptomatic and asymptomatic populations presenting to emergency services to predict the percentage of specimens that would be detected by each assay. A 96-sample paired-swab study was conducted to confirm model results. Results: When using direct nasopharyngeal samples and fit with either VTM or limit-of-detection data, percent positivities for ID NOW (symptomatic 94.9%/97.4%; asymptomatic 88.4.0%/89.6%) and Simplexa (symptomatic 97.8%/97.2%; asymptomatic 91.1%/90.8%) were predicted to be similar. Likewise, percent positivities for ID NOW with direct nasal specimens (symptomatic 77.8%; asymptomatic 64.5%) and, fit with VTM data, Sofia 2 with direct nasopharyngeal specimens (symptomatic 76.6%, asymptomatic 60.3%) were similar. The paired-swab study comparing direct nasopharyngeal specimens on ID NOW and nasopharyngeal VTM specimens on Simplexa showed 99% concordance. Conclusions: Assay performance can be modeled as dependent on viral load, fit using laboratory bench study results, and adjusted to account for direct-specimen testing. When using nasopharyngeal specimens, direct testing on Abbott ID NOW and VTM testing on DiaSorin Simplexa have similar performance.
- 10 November 2021
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (3) , 661-673
Open AccessPredicting Direct-Specimen SARS-CoV-2 Assay Performance Using Residual Patient Samples
Background: Diagnostic sensitivities of point-of-care SARS-CoV-2 assays depend on specimen type and population-specific viral loads. Evaluation of these assays require “direct” specimens from paired-swab studies rather than more accessible residual specimens in viral transport media (VTM). Methods: Residual VTM and limit-of-detection studies were conducted on Abbott ID NOW™ COVID-19, Quidel Sofia 2™ SARS Antigen FIA, and DiaSorin Simplexa™ COVID-19 Direct assays, with cycle threshold (CT) adjustments to approximate direct-specimen testing based on gene-target doubling each PCR cycle. Logistic regression was used to model assay performance by specimen CT. These models were applied to CT distributions of symptomatic and asymptomatic populations presenting to emergency services to predict the percentage of specimens that would be detected by each assay. A 96-sample paired-swab study was conducted to confirm model results. Results: When using direct nasopharyngeal samples and fit with either VTM or limit-of-detection data, percent positivities for ID NOW (symptomatic 94.9%/97.4%; asymptomatic 88.4.0%/89.6%) and Simplexa (symptomatic 97.8%/97.2%; asymptomatic 91.1%/90.8%) were predicted to be similar. Likewise, percent positivities for ID NOW with direct nasal specimens (symptomatic 77.8%; asymptomatic 64.5%) and, fit with VTM data, Sofia 2 with direct nasopharyngeal specimens (symptomatic 76.6%, asymptomatic 60.3%) were similar. The paired-swab study comparing direct nasopharyngeal specimens on ID NOW and nasopharyngeal VTM specimens on Simplexa showed 99% concordance. Conclusions: Assay performance can be modeled as dependent on viral load, fit using laboratory bench study results, and adjusted to account for direct-specimen testing. When using nasopharyngeal specimens, direct testing on Abbott ID NOW and VTM testing on DiaSorin Simplexa have similar performance.
- Top Cited PapersOpen Access
- 6 October 2021
- Published by Elsevier in The Lancet Global Health
- Vol. 9 (11) , e1553-e1560
Availability of essential diagnostics in ten low-income and middle-income countries: results from national health facility surveys
- 6 October 2021
- Published by Elsevier in The Lancet Global Health
- Vol. 9 (11) , e1553-e1560
Top Cited PapersOpen AccessAvailability of essential diagnostics in ten low-income and middle-income countries: results from national health facility surveys
- 13 December 2020
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 6 (1) , 298-303
Inadequate Capacity to Diagnose Cutaneous Infections in Ghana: Extensive Skin Ulceration in a 28-Year-Old Man in the Northern Region
- 13 December 2020
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 6 (1) , 298-303
Inadequate Capacity to Diagnose Cutaneous Infections in Ghana: Extensive Skin Ulceration in a 28-Year-Old Man in the Northern Region